Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed with results

Key Signals

5 with results94% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (5)
P 1 (11)
P 2 (1)
P 3 (2)
P 4 (1)

Trial Status

Completed15
Not Yet Recruiting1
Terminated1
Unknown1
Recruiting1
Enrolling By Invitation1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT06800248Phase 3Not Yet Recruiting

Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

NCT06736691Phase 3Enrolling By Invitation

Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

NCT01940757Phase 1RecruitingPrimary

Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

NCT02143518Phase 1CompletedPrimary

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

NCT06720259Phase 2Completed

Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura

NCT05914363Not ApplicableCompleted

Evaluating Impact of Improved Floors on Health

NCT02839161Phase 1Completed

Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children

NCT01385189Phase 1CompletedPrimary

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

NCT02262403Not ApplicableUnknownPrimary

Hookworm Immune Regulation Project

NCT03373214Phase 1CompletedPrimary

Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults

NCT02476773Phase 1CompletedPrimary

Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults

NCT01717950Phase 1CompletedPrimary

Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults

NCT00939198Not ApplicableCompletedPrimary

Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil

NCT03278431Phase 4CompletedPrimary

Triple Combinations Against Hookworm Infections in Lao

NCT01261130Phase 1CompletedPrimary

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

NCT00120081Phase 1CompletedPrimary

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT02126462Phase 1CompletedPrimary

Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults

NCT00473967Phase 1TerminatedPrimary

Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults

NCT00603889Not ApplicableCompletedPrimary

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

NCT00207753Not ApplicableCompleted

Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections

Showing all 20 trials

Research Network

Activity Timeline